Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) went down by -5.57% from its latest closing price compared to the recent 1-year high of $9.00. The company’s stock price has collected -11.29% of loss in the last five trading sessions. Press Release reported on 02/10/21 that Thinking about buying stock in Zomedica, Zynerba Pharmaceuticals, Cronos Group, Hexo Corp, or AzurRx BioPharma?
Is It Worth Investing in Zynerba Pharmaceuticals Inc. (NASDAQ :ZYNE) Right Now?
Plus, the 36-month beta value for ZYNE is at 2.98. Opinions of the stock are interesting as 5 analysts out of 7 who provided ratings for Zynerba Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $7.42, which is $1.83 above the current price. ZYNE currently public float of 28.60M and currently shorts hold a 14.43% ratio of that float. Today, the average trading volume of ZYNE was 5.02M shares.
ZYNE’s Market Performance
ZYNE stocks went down by -11.29% for the week, with a monthly jump of 49.72% and a quarterly performance of 39.69%, while its annual performance rate touched 12.68%. The volatility ratio for the week stands at 13.74% while the volatility levels for the past 30 days are set at 14.24% for Zynerba Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 13.54% for ZYNE stocks with a simple moving average of 31.37% for the last 200 days.
Analysts’ Opinion of ZYNE
Many brokerage firms have already submitted their reports for ZYNE stocks, with H.C. Wainwright repeating the rating for ZYNE by listing it as a “Buy.” The predicted price for ZYNE in the upcoming period, according to H.C. Wainwright is $9 based on the research report published on December 21st of the previous year 2020.
ROTH Capital gave a rating of “Buy” to ZYNE, setting the target price at $12 in the report published on December 31st of the previous year.
ZYNE Trading at 32.22% from the 50-Day Moving Average
After a stumble in the market that brought ZYNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.78% of loss for the given period.
Volatility was left at 14.24%, however, over the last 30 days, the volatility rate increased by 13.74%, as shares surge +51.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.25% upper at present.
During the last 5 trading sessions, ZYNE fell by -11.29%, which changed the moving average for the period of 200-days by +38.27% in comparison to the 20-day moving average, which settled at $4.87. In addition, Zynerba Pharmaceuticals Inc. saw 64.24% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ZYNE
The total capital return value is set at -51.40, while invested capital returns managed to touch -49.42. Equity return is now at value -74.20, with -63.80 for asset returns.
Based on Zynerba Pharmaceuticals Inc. (ZYNE), the company’s capital structure generated 0.47 points at debt to equity in total, while total debt to capital is 0.47. Total debt to assets is 0.40, with long-term debt to equity ratio resting at 0.15. Finally, the long-term debt to capital ratio is 0.14.
The liquidity ratio also appears to be rather interesting for investors as it stands at 7.20.